Clinical Scorecard: Ramantamig’s trispecific targeting of BCMA and GPRC5D may overcome antigen heterogeneity in multiple myeloma
At a Glance
Category
Detail
Condition
Multiple myeloma, including disease with heterogeneous BCMA and GPRC5D expression
Key Mechanisms
Ramantamig engages CD3 on T cells and targets BCMA and GPRC5D on myeloma cells; the study assessed T-cell-mediated antimyeloma activity.
Target Population
Preclinical cell-line models and bone marrow samples from patients with newly diagnosed or relapsed/refractory multiple myeloma
Care Setting
Preclinical and ex vivo research; the supplied article content does not describe clinical use or patient treatment.
Key Highlights
BCMA and GPRC5D expression levels vary among myeloma cells, and target inactivation has been associated with antigen escape during single-target bispecific antibody therapy.
Ramantamig is a trispecific antibody that targets BCMA and GPRC5D on myeloma cells and CD3 on T cells.
The study evaluated cell-line models and 32 patient bone marrow samples using autologous T cells for ex vivo testing.
Ex vivo efficacy testing was limited to bone marrow samples with at least 1% myeloma cells and sufficient material.
The supplied article excerpt describes study rationale and methods but does not provide efficacy results.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
The article describes variable BCMA and GPRC5D expression and reports that genetic or epigenetic target inactivation has been observed in patients relapsing during BCMA- or GPRC5D-targeting bispecific antibody therapy.
Patient & Prescribing Data
The study cohort included newly diagnosed myeloma and relapsed/refractory myeloma exposed to immunomodulatory drugs and proteasome inhibitors, with or without daratumumab. No double-class- or triple-class-exposed patient had prior bispecific antibody exposure.
Ramantamig was evaluated in preclinical and ex vivo assays; the supplied excerpt provides no clinical dosing, prescribing, safety, or patient outcome data.
Clinical Best Practices
Interpret the findings as preclinical and ex vivo evidence; the supplied excerpt does not establish clinical efficacy or treatment recommendations.
The ex vivo assays assessed primary myeloma-cell lysis and T-cell activation and degranulation in bone marrow mononuclear cells.
by Chloe O'Neill, Marloes E. C. Broekmans, Charlotte L. B. M. Korst, Maria Krevvata, Giada Dal Collo, Richard W. Groen, Bing Li, Serena R. Baglio, Ulrike Philippar, Kodandaram Pillarisetti, Sonja Zweegman, Deeksha Vishwamitra, Tuna Mutis, Niels W. C. J. van de Donk
Breast cancer screening has traditionally been organized around two principal variables: when mammography should begin and how frequently it should be performed.
